Menu
Back to Journals » Drug Design, Development and Therapy » Volume 15
Original Research
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 3,786 | Dovepress* | 3,324+ | 671 | 3,995 | |
| PubMed Central* | 462 | 137 | 599 | ||
| Totals | 3,786 | 808 | 4,594 | ||
| *Since 7 January 2021 | |||||
View citations on PubMed Central and Google Scholar